Letter: Post-Marketing Efficacy of Nemolizumab for Prurigo Nodularis: A Single-Center Study with a Small Sample Size

Abstract

Get full access to this article

View all access options for this article.

References

Williams

, Huang

, Belzberg

, et al. Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol. 2020; 83(6):1567–1575.

Liao

, Cornman

, Ma

, et al. Prurigo nodularis: New insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024; 190(6):798–810.

Kwatra

, Yosipovitch

, Legat

, et al.; OLYMPIA 2 Investigators. Phase 3 trial of Nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023; 389(17):1579–1589.

Yokozeki

, Murota

, Matsumura

. Long-term (68 weeks) administration of Nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥13 years: Efficacy and safety data from a phase II/III study. Br J Dermatol. 2025; 193(1):56–65.

Satoh

, Murota

, Aoyama

, et al. Prurigo chronica multiformis: Expert consensus of the Japanese dermatological association. J Dermatol. 2024; 51(11):e376–e383.